GV.PA Genomic Vision SA on EURONEXT 23 Feb 2026: Intraday most active at €0.0018

GV.PA stock is the day’s most active name on EURONEXT intraday, trading at €0.0018, up 5.88%, on 38,489,238 shares versus a 14,217,513 average. We see a large relative volume spike (2.71x) driving short-term price action. Genomic Vision SA (GV.PA) remains a micro‑cap (€693,191 market cap) listed in Europe in the Healthcare diagnostics sector. As an AI-powered market analysis platform, Meyka AI tracks this move for liquidity, valuation and event risk that matter to short-term traders and long-term speculators.

GV.PA stock: Intraday movers and volume drivers

GV.PA stock is trading near €0.0018 with a day low of €0.0015 and day high of €0.0020. Volume is 38,489,238, well above the 14,217,513 average, which makes GV.PA the most active ticker on EURONEXT in our intraday screen. High relative volume (2.71) points to either news, order book rebalancing, or speculative flows.

Short-term traders should note the 1-day change is +5.88%, while the 3-month change is -77.78%. This setup typically favors momentum plays but carries high execution risk given the stock’s low price and micro-cap liquidity profile.

GV.PA stock: Business snapshot and sector context

Genomic Vision SA (GV.PA) is a France-based molecular diagnostics company offering the FiberVision molecular combing platform and associated consumables. The company reports 330 full-time employees and strategic partnerships including Quest Diagnostics and Institut Pasteur. GV.PA trades on EURONEXT in Europe and competes in Medical – Diagnostics & Research.

Healthcare sector peers have shown modest YTD performance; the sector’s 1Y average return is 4.92%, while diagnostics and biotech micro-caps remain volatile. GV.PA’s product-led model can benefit from diagnostic adoption but remains exposed to clinical validation and commercial scale risks.

GV.PA stock: Financials and valuation snapshot

GV.PA shows a market cap of €693,191, shares outstanding 385,105,984, and trailing EPS -0.11. Price averages sit at €0.00484 (50-day) and €0.013997 (200-day), signaling a long-term downtrend from the 52-week high €0.094 to a low €0.0014. Price/Sales is 0.47 and EV/Sales is 1.60.

Balance-sheet metrics show cash per share €0.00557, current ratio 0.91, and negative book value per share -€0.00944. These figures point to capital constraints and possible dilution risk if management raises cash. The PE is negative, so traditional earnings valuation is not applicable.

GV.PA stock: Technical and trading setup

Intraday technicals for GV.PA stock show support near €0.0014 (52-week low) and immediate resistance at today’s high €0.0020 and moving averages at €0.00484 (50-day). The stock’s average daily volume of 14,217,513 versus today’s 38,489,238 indicates heavier-than-normal selling or buying interest.

For active traders, use tight stops and limit orders. Thin order books at this price level increase slippage and widen spreads. Watch for follow-through volume above 20 million as confirmation of sustained momentum.

GV.PA stock: Meyka AI grade and forecast

Meyka AI rates GV.PA with a score out of 100: 62.53 | Grade: B | Suggestion: HOLD. This grade factors S&P 500 benchmark comparison, sector and industry comparisons, financial growth, key metrics, forecasts, analyst consensus, and fundamental growth. These grades are not guarantees and are for informational purposes only.

Meyka AI’s forecast model projects a 12-month base target of €0.00500, implying +177.78% upside from €0.0018. We model a conservative bear case €0.00100 (-44.44%) and a bull case €0.01500 (+733.33%). Forecasts are model-based projections and not guarantees.

GV.PA stock: Risks and opportunities for traders

Key opportunities include product commercialization, strategic alliances, and any positive validation of FiberVision that can re-rate the stock. Partnerships with larger diagnostics firms would be a clear catalyst. Internal R&D spend (R&D-to-revenue ratio 2.08) supports product development but consumes capital.

Primary risks are extremely low liquidity, negative earnings, potential dilution, and long cash conversion cycles (cash conversion cycle 403.41 days). Short-term volatility is high; institutional coverage is limited. For news context, see recent industry releases and transcripts that affect diagnostic equipment demand source and regional regulatory updates for diagnostics source. Internal Meyka page for trading context: /stock/GV.PA

Final Thoughts

GV.PA stock is a high‑volatility, micro‑cap healthcare name attracting heavy intraday volume on EURONEXT. At €0.0018 with 38,489,238 shares traded and relative volume 2.71, the move is driven by speculative flows and liquidity shifts rather than clear fundamental re-rating. Financials show negative EPS -0.11, limited cash per share €0.00557, and a low current ratio 0.91, which raises dilution and funding risk for longer-term holders. Meyka AI rates GV.PA 62.53 (B, HOLD) and projects a 12-month base target of €0.00500 (+177.78%). Traders should treat intraday strength as a short-term trading opportunity only, size positions carefully, and monitor corporate announcements, partnership news, and any capital raises. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.